Listen to Your Heart

Listen to Your Heart

di Listen to Your Heart
Salute & BenessereScienza della vita
Stagione 3
Secondary prevention: Practical applications in cardiovascular care
What are the key challenges in secondary prevention in cardiovascular care, and how can guidelines be translated into practice to optimize patient management? Our host, Dr. Michael Levi, takes a deep dive into secondary prevention in cardiovascular care, with Dr. Lior Bibas, a cardiologist and critical care physician. In this episode, our experts unpack the core principles of secondary prevention in cardiovascular care, exploring how to minimize recurrent events through targeted lipid management, lifestyle interventions, and evidence-based pharmacologic strategies. From defining optimal LDL, non-HDL, and ApoB thresholds to sequencing different pharmacological agents, the discussion offers a practical roadmap for achieving aggressive lipid lowering in high-risk patients. Discover actionable insights grounded in international guidelines that will strengthen your approach to optimizing cardiovascular risk reduction and delivering long-term protection for patients following a vascular event. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Michael Levi: None. Dr. Lior Bibas: None. MAT-CA- 2600003 V(1.0) App 01/26
S3 · E2
27 feb 2026
16:16
Beyond LDL, lipoprotein A: Role and impact on ACS
How is the evolving understanding of lipoprotein A reshaping our approach to prevention of heart disease? Our host, Dr. Michael Levi, takes a deep dive into this topic with Dr. Lior Bibas, a cardiologist and critical care physician at Pierre Boucher Hospital and the Montreal Heart Institute. In this episode, our experts explain why lipoprotein A is gaining prominence as a key risk factor for cardiovascular disease, discussing its unique properties and clinical implications. They share insights from their clinical practices, revealing how a deeper understanding of specific lipid markers is influencing both primary and secondary prevention strategies and aggressive treatment decisions. Tune in for a glimpse into the future of personalized heart care and emerging therapies that could transform treatment. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Michael Levi: · None. Dr. Lior Bibas: · None. MAT-CA-2501196 V(1.0) App 09/25
S3 · E1
21 ott 2025
17:55
Stagione 2
Improving Adherence to Lipid-Lowering Treatments
Secondary prevention of atherosclerotic cardiovascular disease (ASCVD) often requires the use of lifelong therapies. How can healthcare providers promote adherence to secondary prevention interventions to help high-risk patients achieve their lipid goals? Our host, Dr. Liam Brunham, takes a deeper look into this topic with Dr. Tara Sedlak, a cardiologist at Vancouver General Hospital and BC Women's Hospital, and Director of the Leslie Diamond Women's Heart Health Clinic. Despite the availability of lipid-lowering therapies that reduce the risk of morbidity and mortality, many patients with established ASCVD are not achieving guideline-recommended lipid targets. This episode takes a closer look at some of the factors contributing to this care gap, with a focus on the reasons why patients may be discontinuing their medications. Our experts discuss practical strategies to optimize adherence and secondary prevention for improved outcomes. In addition, they also explore the various ways in which treatments can be personalized to individual patient needs, and how best to support and empower patients in their journey toward optimal lipid management. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Brunham: Direct financial relationship including receipt of honoraria: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Funded grants, research, or clinical trials: Amgen, Novartis, Ionis. Dr. Sedlak: Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Sanofi, KYE Pharmaceuticals, Pendopharm, Boehringer Ingelheim, Eli Lilly, Bayer, Novartis, Pfizer. Membership on advisory boards or speaker’s bureau: Amgen, Novo Nordisk, KYE Pharmaceuticals, Boehringer Ingelheim, Lilly. MAT-CA-2301816 App Dec 2023
S2 · E2
4 nov 2024
18:47
Optimizing Dyslipidemia Management in the Post-STEMI Acute Setting
Following an acute coronary syndrome like non-ST-elevation myocardial infarction (NSTEMI), primary revascularization approaches are the cornerstone for management. What other immediate secondary prevention strategies can be taken to further reduce the residual risk that remains for these patients? Our host, Dr. Liam Brunham, takes a deeper look into this topic with Dr. Jean Grégoire, a cardiologist and clinical researcher working in the Interventional Cardiology Service of the Coronary Care Unit at the Montreal Heart Institute, and Associate Clinical Professor at the Université de Montréal’s Faculty of Medicine. This episode discusses the clinical and anatomical benefits from further intensification of lipid-lowering therapies in high-risk patients, and best practices for management of dyslipidemia post-NSTEMI. Our experts go on to explore some of the clinical evidence supporting earlier use of intensified lipid-lowering therapy in the acute setting—notably, the EPIC-STEMI Study. They also examine how findings from these studies may impact future clinical practice, and how better outcomes may be achieved with more significant reductions in LDL cholesterol. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Brunham: Direct financial relationship including receipt of honoraria: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Funded grants, research or clinical trials: Amgen, Novartis, Ionis. Dr. Grégoire: Membership on advisory boards or speaker’s bureau: Amgen, Boehringer Ingelheim, Eli Lilly, HLS, Novartis, Sanofi, Servier. MAT-CA-2301813 App Dec 2023
S2 · E1
18 set 2024
13:09
Stagione 1
Beyond LDL-C: Lp(a) Levels and Impact on ASCVD Patients
What’s new in lipid management for those with elevated lipoprotein(a) levels ≥60 mg/dL or 120 nmol/L? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with high lipoprotein(a) levels (≥60 mg/dL or 120 nmol/L). Our experts take a deeper dive into recent advances in the understanding of lipoprotein(a) as a risk factor for atherosclerotic disease, and the importance of identifying these high-risk patients. They also discuss how this patient subgroup may benefit from use of more intensive therapies, such as PCSK9 inhibitors, to achieve further LDL cholesterol lowering and reduce the risk of future cardiovascular events and complications. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Manjoo: Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.
S1 · E8
13 set 2022
11:12
Integrated Guidance on Patients with LDL-C >2.6mmol/l and/or HeFH
What’s new in lipid management for people with LDL cholesterol levels ≥2.6 mmol/L or heterozygous familial hypercholesterolemia (FH)? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with high LDL cholesterol (≥2.6 mmol/L) or heterozygous FH. Our experts also take a closer look at why this patient subgroup is at particularly high cardiovascular risk and the importance identifying patients with family history or genetic causes of dyslipidemia. They also discuss how this patient subgroup may benefit from early intensive treatment approaches, such as ezetimibe and PCSK9 inhibitors, to reduce their risk for further cardiovascular complications. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Manjoo: Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.
S1 · E7
13 set 2022
11:13
Secondary Prevention after CABG Surgery in Dyslipidemia Patients
What’s new in lipid management for people who have had previous coronary artery bypass graft (CABG) surgery? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Shaun Goodman, a Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital, and a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto’s Department of Medicine. He is Co-Director of the Canadian VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients who have had heart bypass surgery. Our experts also touch on common misconceptions associated with such patients and the reasons why this subgroup is at higher risk for future cardiovascular events. They discuss the benefits of more aggressive LDL cholesterol lowering therapies in reducing the risk for future complications in those who had CABG surgery, with a particular focus on PCSK9 inhibitors as demonstrated by evidence from the ODYSSEY OUTCOMES Trial. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Goodman: Direct financial relationship including receipt of honoraria: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). Membership on advisory boards or speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma. Funded grants, research or clinical trials: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi.
S1 · E6
13 set 2022
10:51
Dyslipidemia and Recent MI – How do we move on?
What’s new in lipid management for people who have had a myocardial infarction (MI) in the past 2 years? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Shaun Goodman, a Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital, and a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto’s Department of Medicine. He is Co-Director of the Canadian VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients who had an MI in the past 2 years. Our experts touch on the importance of identifying such patients in clinical practice, given their high risk for recurrent major adverse cardiovascular events. They also discuss the evidence supporting intensification of lipid-lowering therapy in this patient subgroup, with a focus on PCSK9 inhibitors, as demonstrated by the ODYSSEY OUTCOMES and FOURIER trials. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Goodman: Direct financial relationship including receipt of honoraria: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). Membership on advisory boards or speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma. Funded grants, research or clinical trials: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi.
S1 · E5
13 set 2022
9:01
Trends and Outcomes of Patients with ACS and Recurrent MI
What’s new in lipid management for people with recurrent myocardial infarction (MI)? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Shaun Goodman, a Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital, and a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto’s Department of Medicine. He is Co-Director of the Canadian VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with recurrent MI. Our experts also dive into the topics of why this patient subgroup is at particularly high risk for subsequent major adverse cardiovascular events and may benefit from more aggressive treatment intensification beyond maximally tolerated statins. They touch on the use of lipid-lowering therapies ezetimibe and PCSK9 inhibitors in those with recurrent MI and discuss the clinical evidence from the landmark ODYSSEY OUTCOMES and FOURIER trials. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Goodman: Direct financial relationship including receipt of honoraria: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). Membership on advisory boards or speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma. Funded grants, research or clinical trials: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi.
S1 · E4
13 set 2022
10:09
PAD and Dyslipidemia – Deciphering the Intricacies of Therapeutic Options
What’s new in lipid management for people with polyvascular disease and symptomatic peripheral arterial disease (PAD)? Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine. This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients wtih polyvascular disease and symptomatic PAD. Our experts expand on why this patient subgroup is at significantly higher risk for future cardiovascular events, highlighting the importance of timely diagnosis and identification of these patients. They also discuss how initiation of more intensive treatments that aim to further lower LDL cholesterol, such as PCSK9 inhibitors, can reduce the cardiovascular risk in these patients. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Thanassoulis: Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence. Dr. Manjoo: Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.
S1 · E3
13 set 2022
10:11
1 di 2